

Semaglutide Added to Basal Insulin in Type 2 Diabetes (Controlled Trial)

Journal of Clinical Endocrinology and Metabolism

103, 2291-2301

DOI: [10.1210/jc.2018-00070](https://doi.org/10.1210/jc.2018-00070)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1–5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2291-2297.	2.2	38
5	Recent updates on GLP-1 agonists: Current advancements & challenges. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 952-962.	2.5	157
6	Semaglutide once-weekly: improved efficacy with a new safety warning. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1061-1072.	1.3	7
7	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2210-2219.	2.2	87
8	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , 2018, 41, 1926-1937.	4.3	49
9	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. <i>Endocrine</i> , 2018, 62, 535-545.	1.1	15
10	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. <i>Diabetes Therapy</i> , 2018, 9, 1533-1547.	1.2	23
11	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019, 43, 136-145.	0.4	50
12	Advances in the treatment of diabetic retinopathy. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107417.	1.2	43
13	<p>>The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2985-2996.	2.0	14
14	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4078-4086.	1.8	25
15	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. <i>Clinical Drug Investigation</i> , 2019, 39, 805-819.	1.1	47
16	Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986269.	1.1	33
18	Subclavian vein stent: Two decades of unassisted patency. <i>Hemodialysis International</i> , 2019, 23, 504-505.	0.4	0
19	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials. <i>Diabetes and Metabolism</i> , 2019, 45, 409-418.	1.4	114
20	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , 2019, 42, 2272-2281.	4.3	225
21	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019, 42, 2262-2271.	4.3	146
22	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 834-844.	5.5	149

#	ARTICLE	IF	CITATIONS
23	Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. <i>Clinical Therapeutics</i> , 2019, 41, 352-367.	1.1	25
24	Improved treatment satisfaction in patients with type 2 diabetes treated with once-a-weekly semaglutide in the SUSTAIN trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2315-2326.	2.2	13
25	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 154, 101-115.	1.1	19
26	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 73.	2.7	69
27	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 528-539.	5.5	156
28	Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. <i>Journal of Medical Economics</i> , 2019, 22, 997-1005.	1.0	18
29	Diabetic Pharmacotherapies in Kidney Disease. , 2019, , 49-74.		0
30	Greater Combined Reductions in HbA1C $\geq 1.0\%$ and Weight $\geq 5.0\%$ with Semaglutide Versus Comparators in type 2 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 589-597.	1.1	10
31	Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 731-738.	2.0	23
32	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 356-367.	5.5	210
33	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <i>Pharmacoeconomics - Open</i> , 2019, 3, 537-550.	0.9	20
35	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019, 20, 805-815.	3.1	71
36	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.	0.6	38
37	Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2745-2753.	1.1	12
38	Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to ≥ 3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). <i>Diabetes and Metabolism</i> , 2020, 46, 100-109.	1.4	220
39	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. <i>Journal of Medical Economics</i> , 2020, 23, 193-203.	1.0	17
40	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	2.2	19
41	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 442-451.	2.2	102

#	ARTICLE	IF	CITATIONS
42	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 543-556.	1.8	24
43	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <i>Diabetologia</i> , 2020, 63, 473-485.	2.9	37
44	Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 7-16.	0.7	6
45	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020, 19, 156.	2.7	25
46	Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 28-42.	0.7	8
47	The trials and tribulations of determining HbA1c targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 717-730.	4.3	39
48	Transitioning to non-insulin therapy in a patient receiving high dose insulin. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 469-475.	0.5	0
49	Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist. <i>Clinical Therapeutics</i> , 2020, 42, 2100-2116.	1.1	3
50	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. <i>BMJ Open</i> , 2020, 10, e037883.	0.8	6
51	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , 2020, 18, 322.	2.3	5
52	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 2509-2518.	4.3	33
53	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2125-2135.	0.9	18
54	Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 43-60.	0.7	47
55	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 880-893.	5.5	86
56	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. <i>Canadian Journal of Diabetes</i> , 2020, 44, 575-591.	0.4	98
57	Long-acting GLP-1RAs. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2020, 33, 3-18.	0.1	16
58	Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 2303-2312.	4.3	54
59	GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. <i>Postgraduate Medicine</i> , 2020, 132, 3-14.	0.9	36

#	ARTICLE	IF	CITATIONS
60	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.	1.2	31
61	Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian <sc>LMC</sc> diabetes registry (<sc>SPARE</sc> study). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2013-2020.	2.2	29
62	Semaglutide injection for the treatment of adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 675-684.	1.3	8
63	Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN-4 and 10. <i>Diabetes Therapy</i> , 2020, 11, 1061-1075.	1.2	3
64	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (<sc>SUSTAIN</sc> 6). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1339-1347.	2.2	18
66	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e015323.	1.6	22
67	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <i>Advances in Therapy</i> , 2021, 38, 550-561.	1.3	5
68	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. <i>International Journal of Clinical Practice</i> , 2021, 75, e13731.	0.8	22
69	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	3.0	518
70	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 754-762.	2.2	134
71	Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. <i>Pharmacoeconomics</i> , 2021, 39, 317-330.	1.7	3
72	The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 221-233.	0.7	10
73	Insulin Dosage Adjustments After Initiation of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002199362.	0.5	0
74	Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2021, 12, 801-811.	1.2	16
75	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1171-1185.	1.6	10
76	Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. <i>Diabetes Therapy</i> , 2021, 12, 1325-1339.	1.2	15
77	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , 2021, 12, 1099-1116.	1.2	8
78	Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2021, 397, 971-984.	6.3	429

#	ARTICLE	IF	CITATIONS
79	An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. <i>Endocrine and Metabolic Science</i> , 2021, 2, 100082.	0.7	4
80	Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5388.	1.2	6
81	Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 626-646.	0.6	6
83	Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 701446.	1.6	3
84	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 503-515.	13.9	668
85	Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. <i>Frontiers in Endocrinology</i> , 2021, 12, 645617.	1.5	42
86	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	1.8	146
87	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-22.	0.9	2
88	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645563.	1.5	66
89	Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108904.	1.1	17
90	Once-a-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes outpatient clinic. <i>Diabetic Medicine</i> , 2021, 38, e14655.	1.2	15
91	Structural principles of insulin formulation and analog design: A century of innovation. <i>Molecular Metabolism</i> , 2021, 52, 101325.	3.0	15
92	Semaglutide and the risk of diabetic retinopathy—current perspective. <i>Eye</i> , 2022, 36, 10-11.	1.1	12
93	Use of once-a-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2269-2278.	2.2	23
94	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108931.	1.1	27
95	Future perspectives in diabetes treatment: Semaglutide, a glucagon-like peptide-1 receptor agonist (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1167.	0.8	7
96	Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis. <i>Current Drug Targets</i> , 2022, 23, 311-327.	1.0	1
97	Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020. , 0, , .		4

#	ARTICLE	IF	CITATIONS
98	Recent developments in <sc>GLP-1 RA</sc> therapy: A review of the latest evidence of efficacy and safety and differences within the class. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 30-39.	2.2	9
99	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 563-574.	5.5	79
100	Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. <i>Diabetes Therapy</i> , 2021, 12, 2891-2905.	1.2	18
101	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. <i>Primary Care Diabetes</i> , 2021, 15, 871-878.	0.9	29
102	Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. <i>Endocrine Journal</i> , 2021, 68, 739-742.	0.7	9
104	Safety of injectable semaglutide for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 785-798.	1.0	10
105	Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> 2020;43:2509-2518. <i>Diabetes Care</i> , 2021, 44, e196-e197.	4.3	1
106	Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 695182.	1.6	9
107	A model-based simulation of glycemic control and body weight when switching from semaglutide to 3.0 and 4.5 mg doses of once-weekly dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2021, 24, 302.	2.2	6
108	Clinical potential of treatment with semaglutide in type 2 diabetes patients. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	4
109	Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. <i>Journal of Investigative Medicine</i> , 2022, 70, 5-13.	0.7	48
113	New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 909-928.	1.8	6
114	Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2021, 42, 101213.	3.2	41
115	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 521-539.	2.6	29
116	Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report. <i>International Journal of Clinical Medicine</i> , 2022, 13, 22-35.	0.1	1
117	Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 534.	3.8	216
118	Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study. <i>Advances in Therapy</i> , 2022, 39, 1582-1595.	1.3	7
119	Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1151-1157.	0.5	3

#	ARTICLE	IF	CITATIONS
120	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. <i>Frontiers of Medicine</i> , 2022, 16, 17-24.	1.5	2
121	Glucagon-Like Peptide 1 Receptor Agonists â€“ Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022, 16, 824054.	1.4	7
122	A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. <i>Cardiovascular Endocrinology and Metabolism</i> , 2022, 11, e0260.	0.5	0
123	Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist NaÃ“ve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria. <i>Diabetes Therapy</i> , 2022, 13, 551-567.	1.2	11
124	GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1657-1665.	1.4	12
125	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	7
126	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002619.	1.2	17
127	Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu. <i>Systemic Hypertension</i> , 2021, 18, 186-192.	0.1	0
128	Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2022, 42, 17-28.	1.1	17
129	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. <i>Biomedicines</i> , 2022, 10, 46.	1.4	10
130	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1587-1598.	1.8	10
131	Semaglutide in type 2 diabetes with chronic kidney disease at high risk progressionâ€”real-world clinical practice. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1593-1600.	1.4	14
132	Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (<sc>SUSTAIN</sc> 11): A randomized, open-label, multinational, phase 3b trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1788-1799.	2.2	18
133	Data-sharing and re-analysis for main studies assessed by the European Medicines Agencyâ€”a cross-sectional study on European Public Assessment Reports. <i>BMC Medicine</i> , 2022, 20, 177.	2.3	9
134	Once-Weekly Semaglutide for Weight Management: A Clinical Review. <i>Journal of Pharmacy Technology</i> , 2022, 38, 239-246.	0.5	3
135	Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102511.	1.8	13
136	Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. <i>Current Atherosclerosis Reports</i> , 2022, 24, 643-654.	2.0	13
138	Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. <i>Nutrients</i> , 2022, 14, 2414.	1.7	7

#	ARTICLE	IF	CITATIONS
139	The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100944.	0.5	12
141	Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. <i>American Heart Journal Plus</i> , 2022, 17, 100163.	0.3	1
142	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 979-994.	2.6	13
143	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	0.6	5
144	Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
145	Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus. <i>Revista Clínica Española</i> , 2022, , .	0.3	0
146	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. <i>World Journal of Clinical Cases</i> , 2022, 10, 6759-6768.	0.3	3
147	Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials. <i>Diabetes Mellitus</i> , 2022, 25, 204-214.	0.5	1
148	Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. <i>Diabetes Therapy</i> , 0, , .	1.2	3
149	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-17.	2.2	36
150	Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4938.	1.0	9
151	Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. <i>Kidney International Reports</i> , 2022, 7, 2345-2355.	0.4	3
153	Semaglutida en enfermedad renal diab�tica: Experiencia en dos programas de salud renal en Colombia. <i>Revista Colombiana De Endocrinolog�a, Diabetes & Metabolismo</i> , 2022, 9, .	0.1	0
154	Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	12
155	Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
156	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. <i>Obesity Medicine</i> , 2022, 35, 100456.	0.5	8
157	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1971-1980.	1.1	3
158	Pharmacotherapy of type 2 diabetes: An update and future directions. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155332.	1.5	35

#	ARTICLE	IF	CITATIONS
159	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. <i>Obesity Facts</i> , 2023, 16, 149-163.	1.6	4
160	Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. <i>Diabetes Therapy</i> , 2023, 14, 93-107.	1.2	2
161	An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal+ Bolus Insulin in Type 2 Diabetes. <i>Diabetes Therapy</i> , 0, , .	1.2	0
162	Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). <i>Cureus</i> , 2022, , .	0.2	2
163	Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. <i>Advances in Therapy</i> , 2023, 40, 920-933.	1.3	9
164	Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from Semaglutide Real-world Evidence (SURE) Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2023, 131, 205-215.	0.6	6
165	Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
166	Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2023, 17, 102696.	1.8	4
167	Efficacy of semaglutide: an evidence-based review. <i>Meditinskiy Sovet</i> , 2023, , 264-273.	0.1	0
168	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4449-4461.	2.0	8
169	Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0278685.	1.1	9
170	Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase III clinical trial programmes. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1385-1397.	2.2	7
171	Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. <i>Journal of Clinical Anesthesia</i> , 2023, 87, 111091.	0.7	39
172	Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudragil Database. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 455-461.	1.0	1
173	Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 161-176.	1.3	2
174	Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1658-1667.	2.2	11
175	Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials. <i>Diabetic Medicine</i> , 0, , .	1.2	0
176	Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. <i>Therapeutic Advances in Psychopharmacology</i> , 2023, 13, 204512532311651.	1.2	7

#	ARTICLE	IF	CITATIONS
198	Pathophysiology-Oriented Treatment of Type 2 Diabetes: 10 Case Reports. , 0, , .		0
199	Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Clinical Drug Investigation, 2023, 43, 915-926.	1.1	0